Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

The American Congress of Physical Medicine and Rehabilitation: Annual Session, 1955
Martin, Gordon M.

Rheumatology | November 20, 2012 | Volume: 3 | Issue: 2 | Pages: 61-63

10.1093/rheumatology/iii.2.61 Get It

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
Bergsagel, P. Leif , Mateos, María‐Victoria , Gutiérrez, Norma C. , Rajkumar, S. Vincent , Miguel, Jesús F. San , Bergsagel, P. Leif , Rajkumar, S Vincent , San-Miguel, Jesus

Blood | November 20, 2012 | Volume: 121 | Issue: 6 | Pages: 884-892

10.1182/blood-2012-05-432203 | PMID 23165477 Get It

Abstract Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for different genetic patient subgroups remains unclear. Unfortunately, the small number of patients in each subgroup frequently limits the analysis of high-risk patients enrolled in clinical trials. Strategies that result in survival of high-risk genetic subgroups approximating that of patients lacking high-risk features are said to overcome the poor prognostic impact of these high-risk features. This outcome has been difficult to achieve, and studies in this regard have so far been limited by inadequate sample size. In contrast, strategies that compare the survival of high-risk genetic subgroups randomized to different treatment arms can identify approaches that improve survival. This type of analysis is clinically useful, even if the absolute gains do not improve outcomes to levels seen in patients without high-risk cytogenetics. Reviewing available data in high-risk MM from this perspective, it appears that bortezomib has frequently been associated with improved survival, whereas thalidomide maintenance has sometimes been associated with a shorter survival.
Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, Carlos , Nin, Verónica , Price, Nathan L. , Capellini, Verena Kise , Gomes, Ana P., Barbosa, Maria Thereza , O’Neil, Luke, White, Thomas A. , Sinclair, David , Chini, Eduardo N. , Sinclair, David A

Diabetes | November 20, 2012 | Volume: 62 | Issue: 4 | Pages: 1084-1093

10.2337/db12-1139 | PMID 23172919 Get It

Metabolic syndrome is a growing health problem worldwide. It is therefore imperative to develop new strategies to treat this pathology. In the past years, the manipulation of NAD+ metabolism has emerged as a plausible strategy to ameliorate metabolic syndrome. In particular, an increase in cellular NAD+ levels has beneficial effects, likely because of the activation of sirtuins. Previously, we reported that CD38 is the primary NAD+ase in mammals. Moreover, CD38 knockout mice have higher NAD+ levels and are protected against obesity and metabolic syndrome. Here, we show that CD38 regulates global protein acetylation through changes in NAD+ levels and sirtuin activity. In addition, we characterize two CD38 inhibitors: quercetin and apigenin. We show that pharmacological inhibition of CD38 results in higher intracellular NAD+ levels and that treatment of cell cultures with apigenin decreases global acetylation as well as the acetylation of p53 and RelA-p65. Finally, apigenin administration to obese mice increases NAD+ levels, decreases global protein acetylation, and improves several aspects of glucose and lipid homeostasis. Our results show that CD38 is a novel pharmacological target to treat metabolic diseases via NAD+-dependent pathways.
Ovarian Cycle and Sympathoexcitation in Premenopausal Women
Carter, Jason R. , Fu, Qi , Minson, Christopher T. , Joyner, Michael J. , Fu, Qi , Carter, Jason R

Hypertension | November 20, 2012 | Volume: 61 | Issue: 2 | Pages: 395-399

10.1161/hypertensionaha.112.202598 | PMID 23172932 Get It

The influence of the ovarian cycle on muscle sympathetic nerve activity (MSNA) remains controversial. Some studies report an increase of resting MSNA during the mid luteal (ML) phase of the ovarian cycle compared with the early follicular phase, whereas other studies do not. These inconsistent findings may be attributable, in part, to the variable surges in estradiol and progesterone. We tested the hypothesis that the degree of sympathoexcitation during the ML phase (ΔMSNA) is associated with changes in estradiol (ΔE 2 ) and progesterone (ΔP). Multiple regression analysis of data from previous studies with complete recordings of mean arterial pressure, MSNA, E 2 , and P during both early follicular and ML phases were available from 30 eumenorrheic women (age, 28±1 years; body mass index, 23±0 kg/m 2 ). ML phase increased E 2 (37±2 to 117±9 pg/mL; P <0.001), P (1±0 to 11±1 ng/mL; P <0.001), and MSNA (12±1 to 15±1 bursts/min; P =0.02), but did not alter mean arterial pressure (83±2 to 83±2 mm Hg; P =0.91). ΔMSNA was correlated with ΔE 2 ( r =−0.50, P =0.003) and ΔE 2 /ΔP ( r =−0.52, P =0.002) but not ΔP ( r =0.21, P =0.13). There was no association between Δmean arterial pressure and ΔE 2 ( r =−0.13, P =0.49), ΔP ( r =−0.04, P =0.83), or ΔE 2 /ΔP ( r <0.01, P =0.98). In conclusion, sympathoexcitation during the ML phase of the ovarian cycle seems to be dependent, in part, on the degree of sex steroid surges. This dynamic interaction among E 2 , P, and MSNA likely explains previously reported inconsistencies in the field; it remains possible that other sex steroids, such as testosterone, might explain further variance.
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study
Kelly, Ciarán P. , Green, P. H. R., Murray, Joseph A. , DiMarino, Anthony J., Colatrella, Anthony M., Leffler, Daniel A. , Alexander, T. , Arsenescu, Razvan, Jiang, John , Arterburn, L. A., Paterson, Blake, Fedorak, Richard N. , Group, the Larazotide Acetate Celiac Disease Study, León, Francisco , Group, the Larazotide Acetate Celiac Disease Study, Murray, J A , Fedorak, R N

Alimentary Pharmacology & Therapeutics | November 19, 2012 | Volume: 37 | Issue: 2 | Pages: 252-262

10.1111/apt.12147 | PMID 23163616 Get It

Summary Background Coeliac disease, an autoimmune disorder triggered by gluten ingestion, is managed by a gluten‐free diet ( GFD ), which is difficult for many patients. Larazotide acetate is a first‐in‐class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated sequelae. Aim To evaluate the efficacy and tolerability of larazotide acetate during gluten challenge. Methods This exploratory, double‐blind, randomised, placebo‐controlled study included 184 patients maintaining a GFD before and during the study. After a GFD run‐in, patients were randomised to larazotide acetate (1, 4, or 8 mg three times daily) or placebo and received 2.7 grams of gluten daily for 6 weeks. Outcomes included an experimental biomarker of intestinal permeability, the lactulose‐to‐mannitol ( LAMA ) ratio and clinical symptoms assessed by Gastrointestinal Symptom Rating Scale ( GSRS ) and anti‐transglutaminase antibody levels. Results No significant differences in LAMA ratios were observed between larazotide acetate and placebo groups. Larazotide acetate 1‐mg limited gluten‐induced symptoms measured by GSRS ( P = 0.002 vs. placebo). Mean ratio of anti‐tissue transglutaminase IgA levels over baseline was 19.0 in the placebo group compared with 5.78 ( P = 0.010), 3.88 ( P = 0.005) and 7.72 ( P = 0.025) in the larazotide acetate 1‐, 4‐, and 8‐mg groups, respectively. Adverse event rates were similar between larazotide acetate and placebo groups. Conclusions Larazotide acetate reduced gluten‐induced immune reactivity and symptoms in patients with coeliac disease undergoing gluten challenge and was generally well tolerated; however, no significant difference in LAMA ratios between larazotide acetate and placebo was observed. Results and design of this exploratory study can inform the design of future studies of pharmacological interventions in patients with coeliac disease.
Febrile Urinary Tract Infections After Ureteroneocystostomy and Subureteral Injection of Dextranomer/Hyaluronic Acid for Vesicoureteral Reflux—Do Choice of Procedure and Success Matter?
Dwyer, Moira , Husmann, Douglas A. , RATHBUN, SUZANNE R., Weight, Christopher , Kramer, Stephen A.

Journal of Urology | November 19, 2012 | Volume: 189 | Issue: 1 | Pages: 275-282

10.1016/j.juro.2012.09.011 | PMID 23174239 Get It

Insulin-like growth factors in the brain and their potential clinical implications
Benarroch, Eduardo E.

Neurology | November 19, 2012 | Volume: 79 | Issue: 21 | Pages: 2148-2153

10.1212/wnl.0b013e3182752eef | PMID 23170013 Get It

Childhood motocross truncal injuries: high-velocity, focal force to the chest and abdomen
Kennedy, Raelene, Potter, D. Dean , Osborn, John B., Zietlow, Scott P., Zarroug, Abdalla E., Moir, Christopher R. , Ishitani, Michael B., McIntosh, Amy L.

BMJ Open | November 19, 2012 | Volume: 2 | Issue: 6 | Pages: e001848

10.1136/bmjopen-2012-001848 | PMID 23166134 Get It

Objectives To review the need for operative intervention and critical care services for motocross truncal injuries in children. Design cohort Retrospective review of patients identified via the hospital trauma registry. Setting Our Level 1 Pediatric Trauma Center serves five motocross tracks. These patients require frequent medical care for injuries. Participants All patients ≤17 years of age with truncal injuries sustained during motocross activities, between 2000 and 2011, were identified through the trauma registry. Primary and secondary outcome measures Operative intervention, intensive care unit (ICU) admission, length of stay, morbidity and demographics were reviewed. Results Motocross injured 162 children. Thirty (18.5%) were thoracic or abdominal injuries. Operative intervention was required in eight (27%) patients. Mean injury severity score (ISS) was 11.8. ICU admission was required in 50% and average hospital length of stay was 4.1 days. The most common injuries include pulmonary contusion, pneumothorax, spleen and liver lacerations. 13% of subjects suffered truncal injury from motocross on more than one occasion. Conclusions Paediatric motocross-related truncal injuries are significant. Surgical intervention is required in 27% of patients. The lower ISS incurred from motocross combined with high surgical and ICU admission rates suggests focal high-impact injuries to the chest and abdomen. Despite significant injury, 13% of motocross patients suffer recurrent injuries. Parents and children need injury prevention education.
Tricyclic antidepressant use and risk of fractures: A meta-analysis of cohort and case-control studies
Qu, Wenchun , Crowell, Michael D. , Hentz, Joseph G. , Frey, Keith A. , Wu, Qing Feng , Crowell, Michael D

Journal of Bone and Mineral Research | November 19, 2012 | Volume: 28 | Issue: 4 | Pages: 753-763

10.1002/jbmr.1813 | PMID 23165455 Get It

Abstract Because studies of the association between tricyclic antidepressant (TCA) treatment and risk of fracture have shown inconsistent findings, we sought to assess whether people who take TCAs are at increased risk of fracture. Relevant studies published by June 2012 were identified through database searches of Scopus, MEDLINE, EMBASE, PsycINFO, ISI Web of Science, and WorldCat Dissertations and Theses from their inception, and manual searching of reference lists. Only original studies that examined the association between TCA treatment and risk of fracture were included. Two investigators independently conducted literature searches, study selection, study appraisal, and data abstraction using a standardized protocol. Disagreements were resolved by consensus. Twelve studies met inclusion criteria. Because of the heterogeneity of these studies, random-effects models were used to pool estimates of effect. Overall, TCA use was associated with significantly increased fracture risk (relative risk [RR], 1.45; 95% confidence interval [CI], 1.31–1.60; p &lt; 0.001). Increased fracture risk associated with TCA use was also observed in studies that adjusted for bone mineral density (RR, 1.54; 95% CI, 1.24–1.90; p &lt; 0.001) or depression (RR, 1.49; 95% CI, 1.28–1.67; p &lt; 0.001). Strength of association with TCA exposure duration ≥6 weeks (RR, 1.13; 95% CI, 1.00–1.28) was substantially weaker than association with TCA exposure duration &lt;6 weeks (RR, 2.40; 95% CI, 1.41–4.08). Prior TCA exposure had no significant effect on fracture risk (RR, 1.04; 95% CI, 0.86–1.26; p = 0.70). After accounting for publication bias, we found the overall association between TCA use and fracture risk to be slightly weaker (RR, 1.36; 95% CI, 1.24–1.50) but still significant (p &lt; 0.001). Findings of this meta-analysis indicate that treatment with TCAs may convey an increased risk of fracture, independent of depression and bone mineral density. © 2013 American Society for Bone and Mineral Research.